History Of EECP2018-11-09T16:41:40+00:00




History of EECP

 

In the 1950s at Harvard University, the first counter-pulsation technology with water hydraulics was created. Soon thereafter, scientists and engineers in China collaborated with Americans to create what we know today as Enhanced External Counterpulsation or EECP. The term Enhanced External Counterpulsation was coined in the 1990’s by Dr. John Hui, a founder of Vasomedical, and his collaborators to describe an improved, proprietary technology for better ECP therapy.

Initial technology was developed to address chronic stable angina pectoris. Several clinical trials were conducted and worldwide, scientists, researchers and academicians have complete studies featuring EECP on a variety of clinical diagnoses.

The EECP Historical Timeline

2007

Vasomedical begins manufacturing the Luminar

Vasomedical stops production of the TS3 and begins manufacturing the Luminar.

2010

“EECP is a Regenerative Therapy”

“EECP is a Regenerative Therapy,” published in Frontiers in Bioscience magazine, clinical researchers from Texas A&M Health Science Center College of Medicine and Cardiology showed that EECP therapy is likely to regenerate circulatory stem cells of diseased organs in the body.

2012

Sara Soulati opens Global Cardio Care-West Los Angeles.

Sara Soulati opens Global Cardio Care-West Los Angeles.

Sara Soulati opens Global Cardio Care-West Los Angeles.

2013

FDA Cardiology Committee

The FDA cardiology committee met to review external counterpulsation. They decided that EECP/ECP had been proven safe and effective in the treatment of refractory angina with patients in clinical studies to lower the classification from Class III to Class II. This permits EECP/ECP devices to be regulated under the 510(k) regulations.

2014

Sara Soulati applies for a patent

Sara Soulati applies for a patent for the Sara Soulati Health for Life Program

2015

Dr. Hui Aligns with Sara in China

Dr. Hui aligns with Sara in China to disclose Vamed’s new generation MC2, now called the MC3. Cedars-Sinai Medical Center in Los Angeles, the University of Chicago Medical School and the American Heart Association publish the results of Sara’s Health For Life Program combined with EECP using the MC2 device. The results detail her program..Read More

Call Us Today!

Receive A Complimentary Experience of Our Clinically Proven Program!

error: